Skip to main content

Table 2 Relationship of the promoter hypermethylation of RASSF1A with clinicopathological features of HCC

From: Identification of RASSF1A promoter hypermethylation as a biomarker for hepatocellular carcinoma

Parameters No. of studies Test for association Test for heterogeneity (Random effect model)
OR 95% CI P I2 (%) P
Age (≥ 50 vs.<50) 6 1.74 [0.82, 3.69] 0.152 0 0.622
Gender (male vs. female) 12 1.36 [0.95, 1.96] 0.094 0 0.894
HBV (positive vs. negative) 12 1.50 [1.05, 2.14] 0.026 0 0.720
HCV (positive vs. negative) 4 0.93 [0.20, 4.26] 0.928 0 0.707
Tumor number (multiple vs. single) 4 0.80 [0.47, 1.36] 0.410 13.9 0.323
Tumor size (≥ 5 cm vs. < 5 cm) 10 1.92 [1.07, 3.42] 0.028 38.8 0.100
Liver cirrhosis (Presence vs. Absence) 9 1.06 [0.60, 1.87] 0.834 55.8 0.021
AFP level (≥ 20 μg/L vs. < 20 μg/L) 6 1.25 [0.47, 3.27] 0.657 61.4 0.024
Histopathological grade (III/IV vs. I/II) 5 1.84 [0.53, 6.36] 0.338 81.3 < 0.001
Tumor differentiation (poor vs. moderate or well) 4 0.91 [0.41, 2.02] 0.820 0 0.778
Portal venous invasion (presence vs. absence) 4 0.61 [0.16, 2.40] 0.481 81.2 0.001
  1. No., number; HBV, hepatitis B virus; HCV, hepatitis C virus; AFP, alpha-fetoprotein; OR, odds ratio; CI, confidence interval
\